U. Idanpaan-Heikkila's research while affiliated with University of Gothenburg and other places
What is this page?
This page lists the scientific contributions of an author, who either does not have a ResearchGate profile, or has not yet added these contributions to their profile.
It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.
If you're a ResearchGate member, you can follow this page to keep up with this author's work.
If you are this author, and you don't want us to display this page anymore, please let us know.
It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.
If you're a ResearchGate member, you can follow this page to keep up with this author's work.
If you are this author, and you don't want us to display this page anymore, please let us know.
Publication (1)
To evaluate the influence of the angiotensin-converting-enzyme inhibitor enalapril (2.5 to 40 mg per day) on the prognosis of severe congestive heart failure (New York Heart Association [NYHA] functional class IV), we randomly assigned 253 patients in a double-blind study to receive either placebo (n = 126) or enalapril (n = 127). Conventional trea...
Citations
... Pharmacological approaches to the treatment of heart failure (HF) have changed dramatically over time. Beginning with the pivotal clinical trials that demonstrated significant efficacy of conventional HF drugs such as angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers (ACEis/ARBs), beta blockers (BBs), and mineral corticoid antagonists (MRAs) in heart failure with reduced ejection fraction (HFrEF) [1][2][3], newer agents such as angiotensin receptor neprilysin inhibitors (ARNis), sodium-glucose cotransporter 2 inhibitors (SGLT2is), hyperpolarization-activated cyclic nucleotide-gated channel (HCN) blockers, soluble guanylate cyclase (sGC) stimulators, and selective cardiac myosin activators, have been reported to provide additive benefits to conventional HF drugs [4][5][6][7][8]. ...
![[object Object]](https://i1.rgstatic.net/ii/profile.image/272340143570952-1441942358353_Q64/Karl-Swedberg.jpg)
